Cumberland Pharmaceuticals Inc. (CPIX)

Over the past six months, Cumberland Pharmaceuticals' stock (CPIX) has experienced notable fluctuations. As of March 27, 2026, the stock price was $3.06, with a market cap of $45.9 million. The stock has seen a decline of 18.89% over the past year, with a 52-week high of $6.27 and a low of $1.85. Key events impacting the stock include the Fourth Quarter 2025 Earnings Report, where the company reported increased revenues but a net loss, leading to a share decline. The company received Fast Track Designation from the FDA for its oral ifetroban therapy for Duchenne muscular dystrophy (DMD) heart disease. Cumberland announced arrangements with RedHill Biopharma Ltd. to jointly commercialize Talicia®, expanding its presence in gastrointestinal care. Approval of Vibativ® in China and its launch in Saudi Arabia, along with regulatory approval for its ibuprofen injection in Mexico, represent significant international milestones. The Centers for Medicare & Medicaid Services (CMS) issued a permanent J-Code for Caldolor®, enhancing access and reimbursement. The stock has shown volatility over the past three months compared to the US market.

The provided search results do not contain explicit information regarding demand seasonality for Cumberland Pharmaceuticals, Inc.'s products and services. Demand for these types of pharmaceutical products is generally driven by ongoing medical needs rather than seasonal variations.

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products, operating within the Pharmaceuticals & Biotech sector and the Drug Delivery industry. The company specializes in providing unique products that improve the quality of patient care, targeting hospital acute care, gastroenterology, rheumatology, and oncology market segments. Its major products include Acetadote® for acetaminophen poisoning, Caldolor® for pain and fever, Kristalose® for constipation, Sancuso® for chemotherapy-induced nausea and vomiting, Vaprisol® for hyponatremia, Vibativ® for serious bacterial infections, and Talicia® for H. pylori infection. The company also has a product candidate, ifetroban, which has completed Phase II clinical trials for various conditions.

Cumberland Pharmaceuticals is headquartered in Nashville, Tennessee, and promotes its approved products through its hospital, field, and oncology sales divisions within the United States. Internationally, Vibativ® has been approved in China and launched in Saudi Arabia, and its ibuprofen injection product has received regulatory approval in Mexico. These international partnerships aim to register and provide medicines to patients in various countries.

Cumberland Pharmaceuticals has demonstrated a focus on advancing patient care through its portfolio of FDA-approved brands and clinical development programs. The company reported strong financial performance in 2025, with solid revenue growth and a profitability turnaround, which generally contributes positively to brand reputation. International expansion efforts, including product approvals and launches in China, Saudi Arabia, and Mexico, also enhance its global standing. The addition of new products like Talicia® and the achievement of important reimbursement milestones for Caldolor® further reflect a positive trajectory in expanding its commercial platform and market access. The FDA granting Fast Track Designation for its DMD oral therapy also highlights the company's commitment to addressing unmet medical needs.

Cumberland Pharmaceuticals Inc. has a mixed ownership structure, with institutional investors owning approximately 16.08% of the company's stock. Insiders own approximately 41.14% of the company's stock, with CEO A. J. Kazimi holding a significant portion. Public companies and individual investors own approximately 42.78% of the stock.